T
Takeharu Yamanaka
Researcher at Yokohama City University
Publications - 317
Citations - 11105
Takeharu Yamanaka is an academic researcher from Yokohama City University. The author has contributed to research in topics: Lung cancer & Bevacizumab. The author has an hindex of 41, co-authored 317 publications receiving 8273 citations.
Papers
More filters
Journal ArticleDOI
Meta-Analysis of Concomitant Versus Sequential Radiochemotherapy in Locally Advanced Non–Small-Cell Lung Cancer
Anne Auperin,Cécile Le Péchoux,Estelle Rolland,Walter J. Curran,Kiyoyuki Furuse,Pierre Fournel,José Belderbos,Gerald H. Clamon,Hakki Cuneyt Ulutin,Rebecca Paulus,Takeharu Yamanaka,Marie-Cecile Bozonnat,Apollonia L.J. Uitterhoeve,Xiaofei Wang,Lesley A. Stewart,Rodrigo Arriagada,Sarah Burdett,Jean-Pierre Pignon +17 more
TL;DR: Concomitant radiochemotherapy, as compared with sequential radiochemicalotherapy, improved survival of patients with locally advanced NSCLC, primarily because of a better locoregional control, but at the cost of manageable increased acute esophageal toxicity.
Journal ArticleDOI
Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
Takashi Seto,Terufumi Kato,Makoto Nishio,Koichi Goto,Shinji Atagi,Yukio Hosomi,Noboru Yamamoto,Toyoaki Hida,Makoto Maemondo,Kazuhiko Nakagawa,Seisuke Nagase,Isamu Okamoto,Takeharu Yamanaka,Kosei Tajima,Ryosuke Harada,Masahiro Fukuoka,Nobuyuki Yamamoto +16 more
TL;DR: Erlotinib plus bevacizumab combination could be a new first-line regimen in EGFR mutation-positive NSCLC and serious adverse events occurred at a similar frequency in both groups.
Journal ArticleDOI
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
Axel Grothey,Alberto Sobrero,Anthony F. Shields,Takayuki Yoshino,James Paul,Julien Taieb,John Souglakos,Qian Shi,Rachel Kerr,Roberto Labianca,Jeffrey A. Meyerhardt,Dewi Vernerey,Takeharu Yamanaka,Ioannis Boukovinas,Jeffrey P. Meyers,Lindsay A. Renfro,Donna Niedzwiecki,Donna Niedzwiecki,Toshiaki Watanabe,Valter Torri,Valter Torri,Mark P Saunders,Daniel J. Sargent,Thierry André,Timothy Iveson +24 more
TL;DR: Among patients with stage III colon cancer receiving adjuvant therapy with FOLFOX or CAPOX, noninferiority of 3 months of therapy, as compared with 6 months, was not confirmed in the overall population.
Journal ArticleDOI
Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography
Kento Imajo,Takaomi Kessoku,Yasushi Honda,Wataru Tomeno,Yuji Ogawa,Hironori Mawatari,Koji Fujita,Masato Yoneda,Masataka Taguri,Hideyuki Hyogo,Yoshio Sumida,Masafumi Ono,Yuichiro Eguchi,Tomio Inoue,Takeharu Yamanaka,Koichiro Wada,Satoru Saito,Atsushi Nakajima +17 more
TL;DR: MRI-based noninvasive assessment of liver fibrosis and steatosis is a potential alternative to liver biopsy in clinical practice and magnetic resonance elastography and proton density fat fraction methods have higher diagnostic performance than TE and CAP methods.
Journal ArticleDOI
The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer.
Takeharu Yamanaka,Shigemi Matsumoto,Satoshi Teramukai,Ryota Ishiwata,Yoji Nagai,Masanori Fukushima +5 more
TL;DR: Measurement of this ratio may serve as a clinically accessible and useful biomarker for patient survival and suggest that the N/L ratio is an independent prognostic factor in advanced gastric cancer.